why choose us

First received: October 27, 2024

Clinical Trial: Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Age-related Macular Degeneration (ARMD)

Study Type: INTERVENTIONAL


Official Title: Efficacy of Switching to Aflibercept 8mg in Patients With Neovascular AMD Showing Limited Response to Faricimab or Aflibercept 2mg

Brief Summary: The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which became globally popular for its effectiveness and safety. Yet, aflibercept did not fully meet all patients' needs. In 2019, brolucizumab showed promising anatomical results but had higher risks of inflammation, limiting its use. Faricimab, introduced in 2022, aimed for longer-lasting…

Read more